Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study Michele B. Kaufman, PharmD, BCGP | April 26, 2018 Reference AbbVie Inc. News release: Upadacitinib meets all primary and ranked secondary endpoints including superiority versus adalimumab in Phase 3 study in rheumatoid arthritis. 2018 Apr 9. Page: 1 2 | Single Page Share: